Timothy A. Yap

26.5k total citations · 9 hit papers
353 papers, 16.3k citations indexed

About

Timothy A. Yap is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Timothy A. Yap has authored 353 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Oncology, 154 papers in Molecular Biology and 99 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Timothy A. Yap's work include PARP inhibition in cancer therapy (90 papers), DNA Repair Mechanisms (67 papers) and Cancer Genomics and Diagnostics (58 papers). Timothy A. Yap is often cited by papers focused on PARP inhibition in cancer therapy (90 papers), DNA Repair Mechanisms (67 papers) and Cancer Genomics and Diagnostics (58 papers). Timothy A. Yap collaborates with scholars based in United States, United Kingdom and Canada. Timothy A. Yap's co-authors include Johann S. de Bono, Funda Meric‐Bernstam, Patrick G. Pilié, Stan B. Kaye, Filip Jankú, Gordon B. Mills, Mark J. O’Connor, Andrew Tutt, Paul Workman and Peter C.C. Fong and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Timothy A. Yap

327 papers receiving 16.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Peter C.C. Fong, David S. Boss et al. profile →
State-of-the-art strategies for targeting the DNA damage response in cancer

2018 795 citations Patrick G. Pilié, Gordon B. Mills et al. profile →
Targeting the PI3K pathway in cancer: are we making headway?

2018 787 citations Timothy A. Yap, Funda Meric‐Bernstam et al. profile →
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

2016 458 citations Timothy A. Yap et al. Cancer Discovery profile →
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

2018 427 citations Jianfeng Shen, Wei Zhao et al. Cancer Research profile →
Development of Immunotherapy Combination Strategies in Cancer

2021 231 citations Timothy A. Yap, Weiyi Peng et al. Cancer Discovery profile →
Antibody-drug conjugates in lung cancer: dawn of a new era?

2023 80 citations Timothy A. Yap, Funda Meric‐Bernstam et al. profile →

Peers

Countries citing papers authored by Timothy A. Yap

Since Specialization

Citations

This map shows the geographic impact of Timothy A. Yap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy A. Yap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy A. Yap more than expected).

Fields of papers citing papers by Timothy A. Yap

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy A. Yap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy A. Yap. The network helps show where Timothy A. Yap may publish in the future.

Co-authorship network of co-authors of Timothy A. Yap

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy A. Yap. A scholar is included among the top collaborators of Timothy A. Yap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy A. Yap. Timothy A. Yap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations 2025 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Kurt W. Evans, Maria Gabriela Raso, (unknown), (unknown), Dhruv Chachad, Timothy P. DiPeri, (unknown), (unknown), Ming Zhao, Argun Akçakanat, Antje M. Wengner, Timothy A. Yap, Funda Meric‐Bernstam	1
2	First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer 2025 ·Clinical Cancer Research ·Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, (unknown), Igor Bondarenko, Toshinari Yamashita, Li Zhou, (unknown), (unknown), (unknown), Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri	5
3	UBA1 inhibition sensitizes cancer cells to PARP inhibitors 2024 ·Cell Reports Medicine ·(unknown), Lacey E. Dobrolecki, (unknown), Xudong Zhang, Li Yang, Sima Khazaei, (unknown), Collene Jeter, Jinsong Liu, Gordon B. Mills, Shannon N. Westin, Michael T. Lewis, Weiyi Peng, Anil K. Sood, Timothy A. Yap, S. Stephen Yi, Daniel J. McGrail, Nidhi Sahni	4
4	First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A 2024 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, (unknown), Rui Li, Gary Wilkinson, Christoph Kneip, Timothy A. Yap	3
5	Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing 2023 ·SHILAP Revista de lepidopterología ·(unknown), Molly S. Daniels, (unknown), Ecaterina E. Dumbrava, Ying Yuan, Keyur P. Patel, (unknown), (unknown), Chetna Wathoo, (unknown), (unknown), Wanlin Wang, Chacha Horombe, Milind Javle, Jordi Rodón, Timothy A. Yap, Banu Arun, Karen H. Lu, Funda Meric‐Bernstam	1
6	Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer 2023 ·SHILAP Revista de lepidopterología ·Ji Son, Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Jordi Rodón, Vivek Subbiah, Apostolia M. Tsimberidou, Timothy A. Yap, Michael Frumovitz, Amir A. Jazaeri, Pedro T. Ramírez, Shannon N. Westin, Ying Yuan, Funda Meric‐Bernstam, David S. Hong	1
7	Precision Combination Therapies Based on Recurrent Oncogenic Coalterations 2022 ·Cancer Discovery ·Xubin Li, (unknown), Gonghong Yan, (unknown), (unknown), (unknown), Jacob H. Elnaggar, Augustin Luna, David G. Menter, Patrick G. Pilié, Timothy A. Yap, Scott Kopetz, Chris Sander, Anil Korkut	20
8	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study 2021 ·Clinical Cancer Research ·Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay, (unknown), Jean‐Charles Soria, Juanita Lopez, Aliénor Berges, (unknown), Itziar Irurzun‐Arana, (unknown), Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, (unknown), Simon A. Smith, Emma Dean, Simon J. Hollingsworth	71
9	ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer 2021 ·Clinical Cancer Research ·Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, Timothy C. Thompson	97
10	Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance 2020 ·Cancer Discovery ·Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord	114
11	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial 2020 ·Clinical Cancer Research ·Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung‐Jue Bang, Chia‐Chi Lin, Wu‐Chou Su, Antoîne Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, (unknown), (unknown), Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna C. Bendell	31
12	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness breakdown → 2018 ·Cancer Research ·Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A. Yap, Gordon B. Mills, Guang Peng	427
13	Precision Oncology Decision Support: Current Approaches and Strategies for the Future 2018 ·Clinical Cancer Research ·Katherine C. Kurnit, Ecaterina E. Dumbrava, Beate C. Litzenburger, Yekaterina B. Khotskaya, Amber M. Johnson, Timothy A. Yap, Jordi Rodón, Jia Zeng, Md Abu Shufean, Ann M. Bailey, Nora Sánchez, Vijaykumar Holla, John Mendelsohn, Kenna M. Shaw, Elmer V. Bernstam, Gordon B. Mills, Funda Meric‐Bernstam	41
14	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors 2017 ·Clinical Cancer Research ·Kurt W. Evans, Erkan Yuca, Argun Akçakanat, Stephen Scott, (unknown), Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, Agda Karina Eterovic, Dalliah M. Black, Jennifer K. Litton, Timothy A. Yap, Debu Tripathy, Gordon B. Mills, Funda Meric‐Bernstam	48
15	Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials 2015 ·Clinical Cancer Research ·Saeed Rafii, Desamparados Roda, Elena Geuna, Begoña Jiménez, Karim Rihawi, Marta Capelán, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji	28
16	Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies 2011 ·Clinical Cancer Research ·David Olmos, Douglas S. Barker, Rohini Sharma, André T. Brunetto, Timothy A. Yap, Anne B. Taegtmeyer, Jorge Barriuso, (unknown), Yan Degenhardt, Alicia J. Allred, Deborah A. Smith, Sharon C. Murray, Thomas A. Lampkin, Mohammed M. Dar, Richard H. Wilson, Johann S. de Bono, Sarah P. Blagden	134
17	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials 2011 ·Clinical Cancer Research ·David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, (unknown), Stan B. Kaye, Johann S. de Bono	21
18	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 2010 ·Molecular Cancer Therapeutics ·Timothy A. Yap, Mike I. Walton, (unknown), Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan T. Henley, Lisa Pickard, Gowri Vijayaraghavan, John Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins, Michelle D. Garrett	59
19	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval breakdown → 2010 ·Journal of Clinical Oncology ·Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye	745
20	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven breakdown → 2008 ·Journal of Clinical Oncology ·Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, J. W. Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono	666

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact